Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
Boston Scientific (BSX) stock was down 1.2% at $44.60 in its latest closing session, underperforming the broader market indexes. The stock has seen a 7.02% drop over the past month, contrasting with gains in the Medical sector. Investors are awaiting its upcoming earnings report on July 29, 2026, with analysts forecasting an EPS of $0.83 and revenue of $5.39 billion, while the company currently holds a Zacks Rank of #4 (Sell).
BSX Downgraded by Evercore ISI Group -- Price Target Lowered to $65
Evercore ISI Group has downgraded Boston Scientific (BSX), lowering its price target from $78.00 to $65.00, while maintaining an Outperform rating. Despite the reduced price target, the company is considered significantly undervalued by GuruFocus's GF Value™ and has a strong GF Score™ of 74/100, driven by high profitability and growth ranks. Insider purchases totaling $554,015 over the last three months also suggest confidence in the stock's future.
J&J's MedTech Segment Eyes Another Strong Quarter in Q2
Johnson & Johnson's (J&J) MedTech division is anticipated to report strong growth in Q2 2026, driven by recent acquisitions in cardiovascular health and new product launches, particularly in electrophysiology. Despite challenges from China's volume-based procurement program, the segment's performance, especially in Cardiovascular, Surgery, and Vision, is expected to reinforce investor confidence in its long-term growth potential. J&J's shares have outperformed the industry this year but are currently valued slightly higher than the industry average.
Top 10 medtech deals in the first half of 2026
Medtech companies engaged in significant merger and acquisition activity during the first half of 2026, building on previous high deal volumes. This period saw $36.5 billion in acquisitions, with companies like Boston Scientific, Medtronic, and Stryker making strategic moves to enter fast-growing markets or divest from slower areas. The top deal was Boston Scientific's $14.5 billion acquisition of Penumbra, alongside other notable transactions by Danaher, Roche, and Agilent.
Catheter Precision, Inc. Announces Issuance of Two Key Patents
Catheter Precision, Inc. (VTAK) has announced the issuance of two new patents related to its medical device technologies. One patent covers European intellectual property for its VIVO technology, aimed at precisely locating cardiac arrhythmias using implantable device data, joining 18 existing patents and applications for VIVO. The second patent is part of the Cardionomix heart failure portfolio, focusing on systems and methods for denoising physiological signals during electrical neuromodulation for acute decompensated heart failure treatment, bringing that portfolio to 33 patents and applications.
Medtronic plc highlights its global medical technology role as investors monitor long-term growth
Medtronic plc, a major player in medical devices, is highlighted for its diversified portfolio and role in global medical technology. Investors focus on the company's long-term growth driven by recurring revenue from implanted therapies, innovation, and its engagement with digital health trends. The article discusses Medtronic's global footprint, revenue drivers, operational efficiency, and the structural tailwinds of an aging population, set against risk considerations like regulatory shifts and pricing pressures.
Boston Scientific Corp. highlights minimally invasive care. Long-term demand supports its medical te
Boston Scientific Corp. specializes in minimally invasive medical devices for various fields like cardiology, endoscopy, and urology. The article highlights the company's diversified portfolio, focus on R&D, and strategic acquisitions, all supported by long-term demand driven by aging populations and the increasing adoption of cost-effective, less invasive medical procedures while emphasizing its commitment to innovation, regulatory compliance, and strong relationships with healthcare providers.
EW - Edwards Lifesciences Corp Volatility & Greeks
This article provides a detailed financial overview of Edwards Lifesciences Corp (EW), including its stock performance, market capitalization, income, sales, and various financial ratios. It also presents insider ownership and institutional ownership data, along with volatility measures and analyst recommendations. The data indicates strong recent performance and growth projections for the company.
Boston Scientific focuses on cardiovascular devices as investors look at long-term growth
Boston Scientific is a global medical technology company specializing in minimally invasive cardiovascular and other interventional devices, attracting long-term investors. The company's diversified portfolio includes products for treating chronic conditions like coronary artery disease and heart rhythm disorders, benefiting from an aging population and continuous innovation in healthcare. Their focus on minimally invasive solutions aims to improve patient outcomes and supports stable revenue streams through repeat procedures and close collaboration with medical professionals.
Becton Dickinson outlines its role in global healthcare. The company’s stock reflects long-term de
Becton Dickinson is a global medical technology company providing medical devices and diagnostic systems worldwide. Its stock performance is influenced by healthcare spending, regulatory developments, and demand for reliable medical equipment. The company's strategy includes organic growth, strategic acquisitions, and significant investment in R&D, focusing on improving patient safety and supporting healthcare professionals.
Smith & Nephew plc highlights its surgical technology portfolio as a global medtech player
Smith & Nephew plc is a global medical technology company specializing in orthopedics, sports medicine, and advanced wound management. The company's diverse portfolio includes products for joint replacement, trauma treatment, and chronic wound care, catering to an international market influenced by aging populations and increasing healthcare demands. This article details the company's business areas, global operations, and commitment to innovation and quality standards.
MDT - Medtronic Plc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Medtronic Plc (MDT). It includes detailed financial metrics such as market capitalization, income, sales, dividend information, various valuation ratios, and performance indicators. The report also highlights institutional and insider ownership, analyst recommendations, and recent stock performance.
KIDS,ATEC Volatility & Greeks
The article provides detailed financial and performance data for two medical device companies: OrthoPediatrics Corp (KIDS) and Alphatec Holdings Inc (ATEC). It includes current stock prices, market capitalization, earnings per share, sales figures, institutional and insider ownership, and various other financial ratios and performance metrics for both companies as of July 2nd.
CLPT - ClearPoint Neuro Inc Volatility & Greeks
This article provides a detailed financial overview of ClearPoint Neuro Inc (CLPT), including its stock performance, key financial metrics, and volatility indicators. It lists various financial ratios, employee and ownership data, and price performance over different periods. The data presented covers the company's valuation, profitability, growth rates, and short interest.
Boston Scientific highlights long-term growth drivers as a global medtech leader
Boston Scientific Corp. is expanding its portfolio in interventional medical devices, focusing on minimally invasive technologies and global market reach for sustained growth. The company emphasizes cardiovascular therapies, neurostimulation, and pain management, leveraging its broad product portfolio and extensive R&D to maintain its competitive position. Its drug-eluting coronary stent platform exemplifies its approach, combining mechanical support with drug delivery to improve patient outcomes and reduce long-term risks.
Does STERIS (STE) Insider Option Exercise Quietly Reframe the Cash Flow and Spending Debate?
STERIS plc director Mohsen Sohi recently exercised options to acquire 3,781 Ordinary Shares, increasing his direct holding to 26,142 shares. This move draws attention as STERIS is known for its steady cash flow and recurring healthcare service demand. The article discusses STERIS's investment narrative, including its share repurchase program and consistent dividends, against the backdrop of ongoing debates about cash flow strength, spending requirements, and potential margin pressures from tariffs and reimbursement changes.
BWAY - Brainsway Ltd ADR Options
This article provides a detailed financial overview of Brainsway Ltd ADR (BWAY), including its recent stock performance, key financial metrics, and valuation ratios. It lists various indicators such as market capitalization, income, sales, P/E ratio, EPS growth, insider and institutional ownership, and profitability margins. The data suggests an in-depth look into the company's financial health and market position.
PEN - Penumbra Inc Volatility & Greeks
This article provides a detailed financial overview of Penumbra Inc (PEN), including its latest stock performance, key financial metrics, volatility data, and analyst recommendations. It covers various fundamental and technical indicators, insider and institutional ownership, and historical performance over different periods.
TMDX - Transmedics Group Inc Latest SEC Filings
This article provides the latest SEC filings information for Transmedics Group Inc (TMDX), along with comprehensive financial data. It includes key figures such as market capitalization, income, sales, various financial ratios, stock performance metrics, and analyst recommendations.
SIBN - SI-BONE Inc Latest SEC Filings
This article provides detailed financial data and performance metrics for SI-BONE Inc (SIBN), including its latest stock price, market capitalization, earnings per share, sales, and various financial ratios. It also lists insider and institutional ownership, analyst recommendations, and recent price performance over different periods. The information is presented as a snapshot of the company's financial health and stock market activity.
Here's What to Expect From F5, Inc.'s Next Earnings Report
F5, Inc. (FFIV) is expected to announce its Q3 2026 earnings soon, with analysts projecting an EPS of $3.04. The company has consistently surpassed Wall Street's EPS estimates in the past four quarters. FFIV's stock performance has outpaced the S&P 500 over the last 52 weeks, and analysts currently hold a "Moderate Buy" rating with a modest upside potential.
BSX Stock Faces Watchman Reset As Analysts Slash Targets
Boston Scientific (BSX) stock has been trading up, despite several analysts cutting their price targets due to slowing U.S. Watchman growth and macro concerns. While growth expectations are being reset, analysts generally maintain a "Buy" rating, pointing to a potential rebound into 2027. The company's strong financials and market demand for its stock suggest that recent volatility is more about adjusted expectations than fundamental issues.
Boston Scientific Corp. focuses on cardiovascular and minimally invasive growth
Boston Scientific Corp. is actively expanding its portfolio of cardiovascular and minimally invasive medical devices, driven by rising global demand for advanced procedures. The company's business model benefits from recurring revenue generated by disposable products, and its shares, listed on a major US exchange, reflect its significant role in the medical technology market. Boston Scientific's offerings include stents, catheters, and implantable cardiac devices, addressing conditions from narrowed blood vessels to structural heart problems.
Boston Scientific (BSX) CFO reports RSU conversion and tax-withheld shares
Boston Scientific's EVP and CFO, Jonathan Monson, recently reported equity compensation activity, converting 2,087 restricted stock units into common stock. Concurrently, 1,010 shares were withheld at $43.06 each to cover tax obligations. Following these transactions, Monson directly holds 39,063 common shares and 6,263 restricted stock units, with future share issuances scheduled in annual installments starting July 1, 2026.
Boston Scientific Corp (BSX) Stock Up 4.8% and Still Undervalued -- GF Score: 74/100
Boston Scientific Corp (BSX) experienced a 4.8% stock increase, yet the company remains significantly undervalued according to GuruFocus's GF Value™ at $45.14 against an estimated fair value of $105.54. With a GF Score™ of 74/100, BSX shows strong profitability and growth despite recent stock price declines. Insider buying totaling $0.6 million further indicates confidence in the company's future prospects.
Boston Scientific Corp. stock outperforms competitors on strong trading day
Shares of Boston Scientific Corp. (BSX) rose 4.83% to $45.14 on Thursday, marking its second consecutive day of gains. This performance occurred on a mixed trading day where the S&P 500 Index remained largely unchanged and the Dow Jones Industrial Average saw a 1.14% increase.
Form 4 Boston Scientific Corp For: 2 July By Investing.com
This article announces a Form 4 filing for Boston Scientific Corp dated July 2nd, as reported by Investing.com. It is a brief announcement without further details within the body of the text, presenting a placeholder for the actual Form 4 content. The article is predominantly filled with navigation links and market data rather than substantive news.
SLS - SELLAS Life Sciences Group Inc Options
This page provides a detailed financial overview of SELLAS Life Sciences Group Inc (SLS), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider/institutional ownership, profitability, and stock performance metrics over different periods. The data indicates recent strong performance with significant percentage increases over weeks, months, and quarters.
INSP - Inspire Medical Systems Inc Options
This article provides a detailed financial overview of Inspire Medical Systems Inc (INSP), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, analyst recommendations, and insider/institutional ownership details. The data suggests a company with significant sales growth in the past but facing challenges in EPS projections and long-term stock performance.
Welltower stock hits all-time high at 234.15 USD
Welltower Inc.'s stock reached an all-time high of $234.15, reflecting strong investor confidence and positive market sentiment in the healthcare real estate sector. The company also reported strong first-quarter 2026 earnings, with Mizuho raising its price target to $239 and maintaining an Outperform rating. Despite a recent shareholder advisory vote against executive compensation, the company's financial performance and strategic initiatives continue to drive its market success.
PHG - Koninklijke Philips NV ADR Volatility & Greeks
This article provides a detailed financial overview of Koninklijke Philips NV ADR (PHG), including its current stock performance, key financial metrics, EPS trends, and insider/institutional ownership data. It presents a snapshot of the company's market position, dividend information, and analyst recommendations.
PHG - Koninklijke Philips NV ADR Earnings
This article provides a detailed financial overview of Koninklijke Philips NV (PHG) ADR, including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, insider/institutional ownership, and analyst recommendations.
RMD - Resmed Inc Latest SEC Filings
This article provides an overview of ResMed Inc. (RMD)'s latest financial data and stock performance as of July 2, 2026. It includes key metrics such as market capitalization, income, sales, dividend information, and various financial ratios. The report also details insider and institutional ownership, profitability margins, and historical stock performance.
Alcon focuses on eye care growth as investors watch long-term strategy
Alcon Inc. is a global eye care company whose future performance hinges on its ability to balance innovation spending with profitability while navigating demographics and technological advancements. The company's diversified portfolio includes surgical equipment, implantable lenses, and consumer vision care products, with its surgical segment being a key pillar due to the high demand for procedures like cataract surgery. Investors are closely monitoring Alcon's long-term strategy to assess how it will continue to create value amidst market competition and regulatory challenges.
Boston Scientific’s Quarterly Earnings Preview: What You Need to Know
Boston Scientific (BSX) is set to release its fiscal 2026 second-quarter earnings on July 29, with analysts expecting diluted EPS of $0.83, a 10.7% increase year-over-year. Despite the company consistently beating EPS estimates and strong Q1 results driven by broad-based demand and new product launches, BSX stock has significantly underperformed the S&P 500 and its sector peers over the past year. Wall Street maintains a "Strong Buy" rating for BSX, with an average price target indicating a potential upside of 71.9%.
Stifel Cuts PT on Boston Scientific Corporation (BSX)- Here’s Why
Stifel cut its price target on Boston Scientific Corporation (NYSE:BSX) to $65 from $75, while reaffirming a Buy rating, citing factors like negative reactions to recent datasets and capacity constraints for Watchman growth slowing. Separately, BofA also reduced its price target to $61 from $68, maintaining a Buy rating, due to a lower utilization environment and a more conservative view on 2027 medtech estimates. Boston Scientific manufactures medical devices across cardiovascular and MedSurg segments.
LMAT - Lemaitre Vascular Inc Latest SEC Filings
This article provides a detailed financial overview and recent SEC filing information for Lemaitre Vascular Inc (LMAT). It includes current stock performance metrics, key financial ratios, insider and institutional ownership data, and various performance indicators across different timeframes. The company's stock closed at $98.74, up 2.90% on July 1st.
PODD - Insulet Corp Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Insulet Corp (PODD). It details key financial metrics, stock performance, analyst recommendations, and insider transaction information, offering a snapshot of the company's current market standing.
DXCM - Dexcom Inc Latest SEC Filings
This article provides the latest SEC filings information and comprehensive financial data for Dexcom Inc (DXCM). It details the company's recent stock performance, key financial metrics such as market cap, income, sales, P/E ratio, and growth rates. The information also includes insider and institutional ownership, profitability margins, and analyst recommendations.
NVCR - NovoCure Ltd Volatility & Greeks
This article provides a detailed financial overview of NovoCure Ltd (NVCR), including its stock performance, key financial metrics, and volatility. It highlights the company's market capitalization, income, sales, and various financial ratios, alongside insider ownership and institutional transactions. The data also covers its recent stock changes, volume, and performance over different periods.
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
Boston Scientific (BSX) stock dropped 1.84% on the latest closing session despite broader market gains, with the S&P 500 up 0.79%. The medical device manufacturer has seen a 9.38% decline in the past month, underperforming its sector and the S&P 500. Investors are anticipating its upcoming earnings report on July 29, 2026, where analysts expect year-over-year growth in both earnings per share and revenue.
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
Boston Scientific (BSX) stock experienced a drop of 1.84% in its latest trading session, contrasting with broader market gains. Despite this recent decline and a 9.38% fall over the past month, the medical device manufacturer is expected to report year-over-year earnings growth of 10.67% and revenue increase of 6.54% in its upcoming earnings report on July 29, 2026. The stock currently holds a Zacks Rank of #4 (Sell) and appears to be trading at a discount compared to its industry peers based on its Forward P/E and PEG ratios.
Boston Scientific Corp. stock outperforms competitors despite losses on the day
Shares of Boston Scientific Corp. (BSX) decreased by 1.84% to $42.68 on Tuesday, even as the broader stock market, including the S&P 500 and Dow Jones Industrial Average, saw gains. This marked the second consecutive day of losses for the company's stock. Despite the daily decline, the article implies Boston Scientific's stock has generally outperformed competitors.
Medtronic PLC Stock (MDT) Closed Down by 3.30% on Jun 30: Key Drivers Unveiled
Medtronic PLC (MDT) stock closed down 3.30% on June 30 due to a broader capital rotation out of defensive healthcare stocks into growth sectors, disappointing fiscal 2027 guidance, and increased trading volatility from FTSE Russell index reconstitution and ex-dividend adjustments. The company faces ongoing challenges including tariff headwinds, regulatory recalls, and intense competition in surgical robotics, despite some positive technical indicators. Analysts maintain a mixed view, with an average price target of $97.91, but significant bearish options activity suggests caution.
Boston Scientific Stock (BSX) Opinions on Recent Analyst Downgrades
This article discusses the recent analyst downgrades of Boston Scientific (BSX) stock, attributing it to softer demand for its Watchman device and overall technical weakness in the market. It also highlights insider trading activity, congressional stock trading, and hedge fund movements related to BSX, alongside recent revenue figures, government contracts, and analyst ratings. The discussion notes both concerns and speculation about a potential recovery for the medical tech company.
EW - Edwards Lifesciences Corp Latest SEC Filings
This article provides the latest SEC filing information for Edwards Lifesciences Corp (EW), detailing various financial metrics, stock performance data, and insider/institutional ownership figures. It also includes key company statistics such as market cap, P/E ratio, sales, and employee count, alongside a summary of recent earnings and sales performance.
Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option
Boston Scientific has invested $1.5 billion for a 34% equity stake in MiRus LLC, a biomaterials and medical implant company. The agreement includes an exclusive option to acquire MiRus's TAVR system for an additional $3 billion if clinical and regulatory milestones are met. This strategic investment aims to bolster Boston Scientific's interventional cardiology portfolio with a differentiated, less invasive treatment option.
Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option
Boston Scientific (NYSE:BSX) has invested $1.5 billion for a 34% equity stake in MiRus LLC, a company that develops advanced biomaterials and medical implants. This deal gives Boston Scientific an exclusive option to acquire MiRus's proprietary TAVR system, which uses a nickel-free rhenium alloy, for an additional $3 billion if certain milestones are met. The partnership aims to enhance Boston Scientific's interventional cardiology portfolio with a new, less invasive treatment option for severe aortic stenosis.
Telix Pharmaceuticals Stock Leads 3 Australian Growth Picks With High Insider Ownership
This article highlights three Australian growth stocks with high insider ownership: Telix Pharmaceuticals (ASX:TLX), Lindian Resources (ASX:LIN), and GemLife Communities Group (ASX:GLF). Telix Pharmaceuticals is noted for its commercial-stage biopharmaceutical operations and cancer therapy pipeline, while Lindian Resources is focused on rare earth deposits with ambitious production targets. GemLife Communities Group capitalizes on the over-50s land lease community trend in Australia.
GE HealthCare adds upgrade pathways for existing Allia interventional imaging systems
GE HealthCare has introduced new upgrade pathways for its Innova, Discovery, and Allia Image Guided Solutions (IGS) systems. These upgrades allow hospitals to modernize existing interventional imaging suites with the latest Allia software, workflows, and imaging technologies without full replacement. The initiative aims to extend the life of equipment, reduce construction needs, and minimize disruptions, addressing the challenge of aging imaging infrastructure in healthcare facilities.
